Page last updated: 2024-09-04

lonafarnib and Hepatocellular Carcinoma

lonafarnib has been researched along with Hepatocellular Carcinoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, D; Huang, Y; Lian, Y; Wang, J; Wei, H; Zeng, G1

Other Studies

1 other study(ies) available for lonafarnib and Hepatocellular Carcinoma

ArticleYear
The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
    Aging, 2019, 08-13, Volume: 11, Issue:15

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Models, Biological; Piperidines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Sorafenib; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays

2019
chemdatabank.com